Atezolizumab Combinations With Chemotherapy for Anaplastic and Poorly Differentiated Thyroid Carcinomas

clinical trial

Details

Instance of: clinical trial
Start time: 27 July 2017
End time: July 2023
Country: United States
Main subject: poorly differentiated thyroid cancer, bevacizumab, carcinoma
clinical trial phase: phase II clinical trial
minimum age: 18
number of participants: 50
research intervention: paclitaxel, bevacizumab, atezolizumab, vemurafenib
sponsor: The University of Texas MD Anderson Cancer Center
study type: interventional study
title: Atezolizumab Combinations With Chemotherapy for Anaplastic and Poorly Differentiated Thyroid Carcinomas

Nothing in the MetaHistoryBook collection references this item yet.